Date:1/28/2010

AP Net Income (Unaudited) (in thousands, except for per share data) Three Months Ended Twelve Months Ended Net income reconciliation January 2, January 3, January 2, January 3, 2010 2009 2010 2009 As Adjusted (1) As Adjusted (1) Net income on a GAAP basis $9,347 $5,325 $28,584 $18,331 Share-based compensation expense: - Cost of product sales 489 466 2,023 1,749 - Selling, general and administrative 1,923 1,743 8,382 6,491 - Research and development 801 690 3,492 2,626 Amortization of Purchased intangibles 2,596 3,296 10,663 13,183 HeartWare transaction costs 1 - 12,314 - Impact of adoption of ASC 470-20 1,945 1,726 7,603 6,946 Unrealized loss on embedded derivative instrument on HeartWare loan 5,240 - - - Income tax effect of non-GAAP adjustments (5,219) (3,381) (16,933) (12,350) Net income on a non-GAAP basis $17,123 $9,865 $56,129 $36,976 Net income per diluted share reconciliation Three Months Ended Twelve Months Ended January 2, January 3, January 2, January 3, ---------- ---------- ---------- ----------
'/>"/>

SOURCE Thoratec Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
5. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
6. Thoratec Presentation at Canaccord Adams Conference to be Webcast
7. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
8. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
9. Thoratec Presentation at Piper Jaffray Conference to be Webcast
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Spherix Reports Second Quarter Earnings